These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 10682134

  • 1. Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine.
    Opravil M, Hill AM, DeMasi R, Dawson D.
    Antivir Ther; 1998; 3(3):169-76. PubMed ID: 10682134
    [Abstract] [Full Text] [Related]

  • 2. Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial.
    Foudraine NA, Jurriaans S, Weverling GJ, Burger DM, Hoetelmans RM, Roos MT, Maas J, Miedema F, Reiss P, Portegies P, de Wolf F, Lange JM.
    Antivir Ther; 2001 Mar; 6(1):55-62. PubMed ID: 11417762
    [Abstract] [Full Text] [Related]

  • 3. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar 10; 14(4):367-74. PubMed ID: 10770538
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
    Goodgame JC, Pottage JC, Jablonowski H, Hardy WD, Stein A, Fischl M, Morrow P, Feinberg J, Brothers CH, Vafidis I, Nacci P, Yeo J, Pedneault L.
    Antivir Ther; 2000 Sep 10; 5(3):215-25. PubMed ID: 11075942
    [Abstract] [Full Text] [Related]

  • 6. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
    Ruiz L, Romeu J, Ibáñez A, Cabrera C, Puig T, Morales MA, Sirera G, Clotet B.
    Antivir Ther; 1996 Dec 10; 1(4):220-4. PubMed ID: 11324824
    [Abstract] [Full Text] [Related]

  • 7. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.
    Murphy RL, Gulick RM, DeGruttola V, D'Aquila RT, Eron JJ, Sommadossi JP, Currier JS, Smeaton L, Frank I, Caliendo AM, Gerber JG, Tung R, Kuritzkes DR.
    J Infect Dis; 1999 Apr 10; 179(4):808-16. PubMed ID: 10068575
    [Abstract] [Full Text] [Related]

  • 8. Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
    Molina JM, Chêuc G, Ferchal F, Journot V, Pellegrin I, Sombardier MN, Rancinan C, Cotte L, Madelaine I, Debord T, Decazes JM, ALBI (ANRS 070) Study Group.
    Antivir Ther; 1999 Apr 10; 4 Suppl 3():71-4. PubMed ID: 16021874
    [Abstract] [Full Text] [Related]

  • 9. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP.
    AIDS; 2008 Jan 30; 22(3):385-93. PubMed ID: 18195565
    [Abstract] [Full Text] [Related]

  • 10. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
    Ibáñez A, Peraire J, Arnó A, Gutiérrez C, Cervantes M, Colomer J, Villalonga C, Camafort M, Ruiz L, Balaguer M, Vidal F, Richart C, Clotet B.
    Antivir Ther; 1997 Apr 30; 2(2):105-11. PubMed ID: 11322274
    [Abstract] [Full Text] [Related]

  • 11. Loss of antiviral effect owing to zidovudine and lamivudine double resistance in HIV-1-infected patients in an ongoing open-label trial.
    Rusconi S, De Pasquale MP, Milazzo L, Moscatelli G, Bulgheroni E, Citterio P, d'Arminio-Monforte A, Moroni M, Galli M.
    Antivir Ther; 1997 Jan 30; 2(1):39-46. PubMed ID: 11322265
    [Abstract] [Full Text] [Related]

  • 12. Four drug-HAART in primary HIV-1 infection: clinical benefits and virologic parameters.
    Capiluppi B, Ciuffreda D, Quinzan GP, Sciandra M, Marroni M, Morandini B, Costigliola P, Guerra L, Di Pietro M, Fibbia GF, Visonà R, Cusini M, Bressi C, Tambussi G, Lazzarin A.
    J Biol Regul Homeost Agents; 2000 Jan 30; 14(1):58-62. PubMed ID: 10763896
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D, Bagnarelli P, Gorin I, Katlama C, Pialoux G, Saimot G, Tubiana P, De Truchis P, Chauvin JP, Mills R, Rode R, Clementi M, Leibowitch J.
    Antivir Ther; 1997 Jul 30; 2(3):175-83. PubMed ID: 11322272
    [Abstract] [Full Text] [Related]

  • 17. Significant reduction in HIV-1 plasma viral load but not in proviral infected cells during sub-optimal antiretroviral therapy.
    Riva E, Antonelli G, Solmone MC, Turriziani O, Narciso P, Tozzi V, Dianzani F.
    J Biol Regul Homeost Agents; 2000 Jul 30; 14(1):1-3. PubMed ID: 10763882
    [Abstract] [Full Text] [Related]

  • 18. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens.
    Rinaldo CR, Liebmann JM, Huang XL, Fan Z, Al-Shboul Q, McMahon DK, Day RD, Riddler SA, Mellors JW.
    J Infect Dis; 1999 Feb 30; 179(2):329-36. PubMed ID: 9878015
    [Abstract] [Full Text] [Related]

  • 19. Drug combination shows benefits for AIDS patients with history of taking AZT.
    AIDS Patient Care STDS; 1996 Jun 30; 10(3):185-6. PubMed ID: 11361628
    [No Abstract] [Full Text] [Related]

  • 20. Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy.
    de Mendoza C, Soriano V, Pérez-Olmeda M, Rodés B, Casas E, González-Lahoz J.
    J Hum Virol; 1999 Jun 30; 2(6):344-9. PubMed ID: 10774551
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.